文献速递临床试验与 GCP流行病学与生物统计

简化联合方案治疗儿童急性营养不良的非劣效性试验

A simplified, combined protocol versus standard treatment for acute malnutrition in children 6-59 months (ComPAS trial): A cluster-randomized controlled non-inferiority trial in Kenya and South Sudan.
PubMed 文献 · PLoS Med · 2020-07-09

在肯尼亚和南苏丹开展的整群随机非劣效性试验显示,针对6-59月龄急性营养不良儿童的简化联合方案(统一治疗严重和中毒急性营养不良)在营养恢复方面不劣于标准方案。联合方案组恢复率为76.3%,标准方案组为73.5%,风险差0.03(95%CI -0.05至0.10,P=0.52)。联合方案每名恢复儿童所需即食治疗食品更少(122 vs 193袋),成本更低(918 vs 1041美元)。

要点

  • 联合方案在营养恢复方面不劣于标准方案,风险差0.03(95%CI -0.05至0.10)。
  • 联合方案每名恢复儿童所需即食治疗食品更少(122 vs 193袋)。
  • 联合方案每名恢复儿童成本更低(918 vs 1041美元)。

核心结论

  • 针对6-59月龄儿童严重和中毒急性营养不良的联合治疗方案在营养恢复方面不劣于标准治疗。

研究设计与样本

  • 在肯尼亚和南苏丹开展的整群随机非劣效性试验,按国家分层随机。
  • 联合方案组12个诊所共2071名儿童(平均年龄17.4月,41%男性),标准方案组12个诊所共2039名儿童(平均年龄16.7月,41%男性)。
  • 非劣效性界值为10%,主要分析为符合方案分析,同时进行意向性分析。

主要发现

  • 联合方案组981名(76.3%)和标准方案组884名(73.5%)儿童达到营养恢复,风险差0.03(95%CI -0.05至0.10,P=0.52)。
  • 联合方案组每名严重急性营养不良儿童达到完全恢复所需即食治疗食品或即食补充食品为122袋,标准方案组为193袋。
  • 联合方案组每名恢复儿童成本为918美元,标准方案组为1041美元,联合方案节省123美元。
  • 联合方案组死亡23例(1.8%),标准方案组死亡21例(1.8%),调整风险差95%CI -0.01至0.01,P=0.87。
  • 其他次要结局(成本效果、覆盖率、失访、住院时间、平均每日体重和上臂围增长)两组间无差异证据。

关键数值与推荐

  • 联合方案诊所:上臂围<11.5 cm和/或水肿者每日2袋即食治疗食品;上臂围11.5至<12.5 cm者每日1袋即食治疗食品。
  • 标准方案诊所:严重急性营养不良按体重给予即食治疗食品,中毒急性营养不良给予即食补充食品。
  • 非劣效性界值为10%。

临床怎么用

  • 简化联合方案可替代区分严重和中毒急性营养不良的复杂标准方案,降低治疗复杂性和成本。
  • 联合方案可减少每名恢复儿童所需即食治疗食品数量并降低人均成本。

局限性

  • 环境因素导致失访。
  • 采用多国合并的功效估计。
  • 存在操作性限制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Malnutrition underlies 3 million child deaths worldwide. Current treatments differentiate severe acute malnutrition (SAM) from moderate acute malnutrition (MAM) with different products and programs. This differentiation is complex and costly. The Combined Protocol for Acute Malnutrition Study (ComPAS) assessed the effectiveness of a simplified, unified SAM/MAM protocol for children aged 6-59 months. Eliminating the need for separate products and protocols could improve the impact of programs by treating children more easily and cost-effectively, reaching more children globally. METHODS AND FINDINGS: A cluster-randomized non-inferiority trial compared a combined protocol against standard care in Kenya and South Sudan. Randomization was stratified by country. Combined protocol clinics treated children using 2 sachets of ready-to-use therapeutic food (RUTF) per day for those with mid-upper arm circumference (MUAC) < 11.5 cm and/or edema, and 1 sachet of RUTF per day for those with MUAC 11.5 to <12.5 cm. Standard care clinics treated SAM with weight-based RUTF rations, and MAM with ready-to-use supplementary food (RUSF). The primary outcome was nutritional recovery. Secondary outcomes included cost-effectiveness, coverage, defaulting, death, length of stay, and average daily weight and MUAC gains. Main analyses were per-protocol, with intention-to-treat analyses also conducted. The non-inferiority margin was 10%. From 8 May 2017 to 31 March 2018, 2,071 children were enrolled in 12 combined protocol clinics (mean age 17.4 months, 41% male), and 2,039 in 12 standard care clinics (mean age 16.7 months, 41% male). In total, 1,286 (62.1%) and 1,202 (59.0%), respectively, completed treatment; 981 (76.3%) on the combined protocol and 884 (73.5%) on the standard protocol recovered, yielding a risk difference of 0.03 (95% CI -0.05 to 0.10, p = 0.52; per-protocol analysis, adjusted for country, age, and sex). The amount of ready-to-use food (RUTF or RUSF) required for a child with SAM to reach full recovery was less in the combined protocol (122 versus 193 sachets), and the combined protocol cost US$123 less per child recovered (US$918 versus US$1,041). There were 23 (1.8%) deaths in the combined protocol arm and 21 (1.8%) deaths in the standard protocol arm (adjusted risk difference 95% CI -0.01 to 0.01, p = 0.87). There was no evidence of a difference between the protocols for any of the other secondary outcomes. Study limitations included contextual factors leading to defaulting, a combined multi-country power estimate, and operational constraints. CONCLUSIONS: Combined treatment for SAM and MAM is non-inferior to standard care. Further research should focus on operational implications, cost-effectiveness, and context (Asia versus Africa; emergency versus food-secure settings). This trial is complete and registered at ISRCTN (ISRCTN30393230). TRIAL REGISTRATION: The trial is registered at ISRCTN, trial number ISRCTN30393230.

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Bailey J, Opondo C, Lelijveld N, et al. A simplified, combined protocol versus standard treatment for acute malnutrition in children 6-59 months (ComPAS trial): A cluster-randomized controlled non-inferiority trial in Kenya and South Sudan. PLoS Med. 2020. PMID: 32645109. doi:10.1371/journal.pmed.1003192

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。